“…Different SARS-CoV-2 targeting bsAbs have been described, which show improved neutralization activity compared to the parental mAbs 18,20,21 . The so far described IgG-like bsAbs are of highly diverse formats, such as the CrossMAb constructs [22][23][24][25][26] , DVD-Ig 24,27 , IgG-(scFv)2 21,24,28,29 , Tandem scFv-Fc 28,30,31 , and VH/Fab IgGs 32,33 , many of which require significant engineering and quality control processes to be efficiently produced. Additionally, most of these bsAbs usually target at least one exposed and non-conserved epitope, which can make them susceptible to viral escape.…”